Mesenchymal stem cells (MSC) implanted into the brain have shown strong neurorestorative effects in animal models of Huntington's disease (HD) and other neurodegenerative disorders. In the brain tissue, MSC reduce inflammation, neutralize reactive oxygen species, and diminish apoptosis to delay the loss of neurons. For the past 20-plus years, our group has studied the biosafety of human MSC engineered to produce cytokines and other factors in vivo, and we have shown sustained expression in many tissues for at least 18 months. However, low numbers of MSC cross the blood-brain barrier in our chronic disease models. Intracranial (IC) implantation of MSC and brain-derived neurotrophic factor (BDNF)-modified MSC have been shown to be safe and effective in rodent HD models. Clinical trials of MSC infusion into the brains of humans with ALS and traumatic brain injury have been done without adverse events, but therapies using this IC delivery route for MSC have not yet been initiated in the U.S.A. through FDA-approved trials. Our ongoing studies are evaluating the biosafety of MSC and then inducible BDNF-modified MSC implantation into the brains of rodents and non-human primates to generate data for the FDA in support of an initial planned phase 1 clinical trial to treat HD. We will next validate the biosafety of our patented approach to use MSC to directly deliver small interfering RNA (siRNA) into damaged and at-risk neurons for the second planned trial. SiRNA directed against mutant huntingtin mRNA are effective at ameliorating the neurodegenerative effects seen in HD and other disorders, since the mutant protein is no longer made. But it is very difficult to get siRNA across the blood-brain barrier in human patients, which has thwarted effective clincial use. We have shown that MSC can move nimbly through tissues and deliver their contents directly into target cells. Thus, for the second planned trial, we will use MSC to continually deliver anti-mutant htt siRNA directly into damaged striatal neurons, to reduce levels of mutant htt RNA and protein. Since there are currently no cures or highly effective treatments for HD, there is a high potential benefit-to-risk ratio for these studies. Background: An original primary aim of PREDICT-HD was identification and quantification of clinical marker sets predictive of HD diagnosis. Such models would add substantial power and efficiency to eventual clinical trials to prevent or delay HD onset. Since the study's inception, skepticism has grown regarding the utility of "diagnosis" as an HD concept. For this analysis, we assume that illness transition can at least be crudely dichotomized by an abstract point of "diagnosis." Nonetheless, we see substantial evidence of inter-rater variability in defining this point and make appropriate statistical adjustments. Methods: As of April 2009, 2179 years of pre-diagnosis follow-up were available on 718 participants, 126 of whom had been diagnosed by UHDRS confidence level 4. We constructed multivariate models predicting "diagnosis" from the study's non-brain-imaging baseline measures. Various criteria consistently selected from among candidate variables each individually predictive of diagnosis were used. Models were tested for additional prediction beyond that achieved by CAG length and age. Cox proportional hazard modeling was used, with stratification by rater in order to minimize systematic differences in diagnostic thresholds and motor scoring.
Results:
The combined baseline measures of maximum tapping speed, paced tapping precision, Stroop inference, and smell identification accuracy were highly predictive. Estimated hazard ratio increased 5.39 across the interquartile range of estimated risk (p Ͻ0.0001). Adding a previously defined CAGbased predictor, smell identification lost significance. The other three variables still added substantial additional prediction. When rater motor score was added, speeded and paced tapping remained highly informative.
Conclusion:
The relative risk of transition to HD "diagnosis" is predictable using measures that have played little traditional role defining diagnosis. This demonstrates important practical utility for these predictors. Absent a highly reliable, continuous measure of early HD, the success of these results also affirms the potential value of reliable discrete endpoints for early-HD trials. Clinical trials to evaluate the safety and effectiveness of cell therapy products are regulated by the U.S. Food and Drug Administration (FDA). One of the most critical junctures in the development of a new therapeutic agent is the transition from the bench to the first clinical trials. To determine whether there is information to support initiation of a clinical trial, and whether the investigation is adequately designed to assure the safety of subjects, the FDA reviews information on the product, preclinical safety studies, and safety features incorporated into the clinical trial. Product information can include, for example, information on source controls and manufacturing process controls, as well as analytical assessment of product characteristics and safety testing for adventitious agents or other contaminants. Preclinical safety evaluation is important to establish a scientific rationale for the clinical investigation of the product and to demonstrate an acceptable safety profile of the cell therapy and its delivery system. Early stage trials are reviewed for safety. Study design aspects that enhance safety include, for example, defining an appropriate patient population, and incorporation of safety monitoring and stopping rules into the trial. Early stage trials can provide early information about safety and tolerability, as well as information on dose selection and dose delivery, proof of concept, patient selection, and information to assist in selection of clinical trial design parameters for pivotal studies. Dialogue with the FDA is encouraged during early stages of product development in order to provide investigators and sponsors with an understanding of what is needed to initiate clinical development, and at later stages to discuss what type of data would be needed to support a marketing application.
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Results:
The mean score on the questionnaire was 55%, indicating suboptimal quality of life. The single item self-reported QOL question correlated with the total score on the HDQoL-C (r ϭ 0.67, p Ͻ 0.05). The number of hours spent care giving and working correlated inversely with QOL (r ϭ Ϫ0.43, p Ͻ 0.05 and Ϫ0.43, p Ͻ 0.05, respectively). The number of times a caregiver socialized per month was positively correlated with the HDQoL-C total score (r ϭ 0.52, p Ͻ 0.01). Subjects most often reported in the comments of the two free-text questions that access to affordable care programs for the HD-affected person, more time for themselves, and social support would improve their QOL. Conclusions: Providing respite from care giving specifically involving social activities may improve HD caregiver QOL. Further studies involving specific interventions to improve HD caregiver QOL are warranted. We secured a grant from the Legal Services Board of Victoria to fund a follow-on project from RESPOND-HD to analyze and explore the Australian experience of genetic discrimination (GD), using HD as a case model. The objectives are 1) improving knowledge of laws related to GD, 2) improved legal services, and 3) development of easily accessible resources (brochure, website) informing consumers of their rights. Results: Of 60 participants (65% female; 35% male; 60% HD gene positive; 40% gene negative), aged between 20 and 69 years, 32% reported experiencing GD, with mean number of incidences 3.17 (Ϯ3.35). Participants experienced discrimination in employment, social, and insurance domains. For example, 17% of respondents had been refused insurance coverage, 20% offered coverage only at a higher premium, 55% told because of family history they could get only limited coverage, and 36% told that due to test results they could get only limited coverage.
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Responses to Discrimination:
1. Action-getting involved in activities 2. Inaction-do nothing, react with positivity, feel surprised by discrimination 3. Involvement-information provision, research involvement 4. Advice-regarding event or potential for event 5. Advocacy-to reduce stereotyping, providing education Awareness of Legislation: Victoria's anti-discrimination laws are contained in the Equal Opportunity Act 1995, Disability Discrimination Act 1992, and Human Rights and Equal Opportunity Commission Act 1986. Regarding GD, 17% of participants knew where to make a complaint; 27% knew of laws preventing employers from unfairly using genetic information; 15% knew of laws preventing health insurance companies from accessing or requiring genetic information about an insured person; and 10% knew of laws preventing these companies from using genetic information to deny insurance. We aim to increase these percentages. We are funded to hold focus groups to discuss results and clarify issues with several cohorts (genenegative participants, gene-positive participants, family members, case workers, health professionals, and researchers), and also for a public launch of the above-mentioned resources. Background: Epileptic seizures are a common feature of juvenile Huntington's disease (JHD), yet very little is known about the frequency of seizures, seizure type, electroencephalographic (EEG) characteristics, and response to anti-epileptic drugs (AEDs) in this subset of patients, much less about what correlates with increased seizure risk. Methods and Results: Via retrospective chart review, we evaluated the frequency of seizures in our JHD population. Since inception, our clinic has seen 13 patients with genetically confirmed JHD. Incomplete medical records necessitated exclusion of three patients from our review. Of the 10 remaining patients, 5 (50%) were being treated for paroxysmal events presumed to be seizures. Semiology was variable and included staring spells, hypertonicity with vocalizations, generalized convulsions, and myoclonic events. EEG data were available for 4 patients. One had a normal EEG. Two had diffuse background slowing with no obvious epileptiform abnormalities. One had a background of 2.5-4 Hz delta slowing that was monomorphic at times; she also had nearly continuous, bilateral parietaloccipital 2.5-3.0 Hz spike and slow wave discharges and occasional spike wave discharges seen in a more generalized distribution. Discussion: Although the focality of the spike and slow wave discharges is suggestive of localization-related epilepsy, the presence of more generalized spike wave discharges suggests symptomatic generalized epilepsy. AEDs used in these patients included valproic acid, lamotrigine, levetiracetam, and alprazolam. All were managed effectively with monotherapy, except the child with epileptiform abnormalities on her EEG; she experienced an increase in her seizure frequency on levetiracetam monotherapy. Lamotrigine monotherapy was ineffective, and she is now on a combination of valproic acid and lamotrigine in attempt to reduce her seizure frequency from her current rate of 3 events per week. Expanding our understanding of the mechanism and best treatment of seizures in JHD will require analysis of data from multiple HD centers. Background: Huntington's disease (HD) is a hereditary neurodegenerative disease in which balance and gait impairments inevitably develop, placing individuals at high risk for injurious falls and lowering their quality of life. Methods: In a study designed to examine the efficacy of an exercise program using the video game Dance Dance Revolution (DDR) to improve balance and mobility in individuals with HD, participants will be 20 adults with HD who can ambulate 10 feet without assistance. A randomized, cross-over, control design is used. Subjects are alternately assigned to experimental (n ϭ 10) and control (n ϭ 10) groups. The experimental group performs DDR for 45 minutes 2ϫ/week for 6 weeks in their homes with a researcher who provides instructions. The control group performs a hand-held video game that controls for the effects of the attention and novelty of the DDR intervention. After completing the initial intervention, the control group crosses over to the DDR intervention and the experimental group performs the hand-held video game. Compliance with the control phase and fall incidence is determined via weekly phone calls. All outcome measures including the Tinetti Mobility Test (TMT), the 4-square step test, the Activities-Specific Balance Confidence (ABC) scale, forward, backward, and obstacle course spatiotemporal gait measures using the GaitRite walkway, and subjects' reported perceptions of the video games are obtained by one of the researchers, who is blinded to group assignment. Results and Discussion: Preliminary data analysis of subjects who have completed the study (n ϭ 7) shows a trend for improvements in balance measures such as the TMT and performance on an obstacle course following the DDR intervention. The majority of subjects report that the DDR game is fun, challenging, and highly motivating, whereas the hand-held games tend to be difficult and inconvenient to play. The preliminary results indicate that DDR is well tolerated, and may improve balance in this population. Methods: HD subjects (n ϭ 49) were tested on both the MMSE and MoCA in counterbalanced order at baseline and approximately 1 year later. Subjects who declined were compared with those who did not on multiple clinical features. Results: The overall group of HD subjects showed a mean age of 50.8 (SD ϭ 12.9) yrs, education of 13.9 (SD ϭ 2.5) yrs, Independence Scale score of 70.5 (SD ϭ 11.3), and CAG repeats of 44.7 (SD ϭ 3.9). Mean baseline scores were 24.5 (SD ϭ 3.5) on the MMSE and 20.0 (SD ϭ 5.1) on the MoCA. The annualized rate of change for HD subjects was 0.72 points per year on the MMSE and 1.1 points per year on the MoCA. Approximately one half of subjects did not decline over time.
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Of those who did, annualized rates of change were 2.3 points on the MMSE and 2.5 points on the MoCA. When subjects who declined were compared with those who did not, there were no significant differences with regard to most clinical and demographic features (including age, education, CAG repeats, UH-DRS motor score, baseline MMSE or MoCA scores). Only the Independence Scale suggested a difference between those who declined (mean ϭ 67.0; SD ϭ 9.8) on the MMSE vs those who did not (mean ϭ 74.3; SD ϭ 12.1, p ϭ 0.026). Conclusions: Both the MMSE and MoCA appear to have utility as brief cognitive instruments in HD. Surprisingly, although the MoCA may be better for detecting cognitive deficits, the MMSE, which better reflects functional decline, may be more useful for tracking disease progression. Background: Searching brain and peripheral biomarkers is a requisite to cure for Huntington's disease (HD). Mutated huntingtin exerts its main pathological effects on brain neurons. Neuronal dysfunction and degeneration cause progressively invalidating extrapyramidal symptoms, cognitive decline, and behavioral changes. Neuropathological studies showed progressive striatal dysfunction and degeneration since the beginning of the disease. Methods: We analyzed the cross-sectional and longitudinal rate of brain atrophy, quantitatively measured by fully automated multiparametric magnetic resonance imaging, as fractional gray matter (GM, determining brain cortex volume), white matter (WM, measuring the volume of axonal fibers), and corresponding cerebrospinal fluid (CSF, a measure of global brain atrophy), in 94 gene-positive subjects with pre-symptomatic to advanced HD and age-matched healthy controls. Results and Discussion: Each of the three brain compartments we studied (WM, GM, and CSF) had a diverse role, and their time courses differed in the development of HD. GM volume decreased early in life. Its decrease was associated with decreased serum brain derived neurotrophic factor and started even many years before onset symptoms, then decreased slowly in a nonlinear manner during the various symptomatic HD stages. WM volume loss also began in the pre-symptomatic stage of HD, a few years before manifest symptoms appear, rapidly decreasing near to the zone-of-onset. Finally, the CSF volume increase began many years before age at onset. Its volume measured in pre-symptomatic subjects contributed to improving the CAG-based model of age at onset prediction. The progressive CSF increase depended on CAG mutation size and continued linearly until the last stages of HD since the pre-symptomatic life stage, representing the best marker of progression rate and severity in HD (R 2 ϭ 0.25, p Ͻ 0.0001) and improving the CAG-based prediction of age at onset. Background: TRACK-HD is a multi-center, longitudinal study investigating a range of motor, cognitive, neuropsychiatric, and imaging measures as potential biomarkers for clinical trials in Huntington's disease (HD). Psychiatric assessments were conducted using a 10-item semi-structured interview, the short version of the Problem Behaviours Assessment for HD (PBA-s). Interviews were video recorded for quality assurance purposes, and a proportion randomly selected for re-scoring at another site. The study therefore provided an opportunity to examine the reliability of the measure between multiple pairs of raters in different cultural and linguistic contexts. Methods: The study included 360 subjects (120 affected, 120 premanifest gene carriers, 120 controls), and 185 interviews were selected for re-scoring by an expert rater. Digital video recordings were uploaded to the TRACK-HD Web portal and selected for re-scoring by an independent investigator blind to the subjects' diagnosis. A further 73 interviews were obtained from the REGISTRY clinic in Manchester and used for training the expert raters. Results: Complete agreement between raters was achieved for 86% of scores ( ϭ 0.733), and 97.6% were within one point of the expert rating, the standard for quality assurance purposes. Agreement levels for individual pairs of raters ranged from 75% to 94% ( ϭ 0.59 -0.86); agreement within one point ranged from 92% to 99%. Complete agreement for the 20 individual ratings (10 symptoms * frequency and severity) ranged from 67% to 100% ( ϭ 0.56 -0.97); agreement within one point ranged from 94% to 100%.
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Conclusions:
The overall results indicate substantial agreement between all raters, whereas the -statistic for individual rater pairs ranged from 'moderate' to 'almost perfect' agreement, with almost all raters achieving at least a 'substantial' level of agreement. These data suggest that the PBA-s, with appropriate training, is a reliable measure of psychiatric symptoms in the HD population. Background: TRACK-HD is a multi-center, longitudinal study investigating a range of motor, cognitive, neuropsychiatric, and imaging measures as potential biomarkers for clinical trials in Huntington's disease (HD). Psychiatric assessments were conducted using a 10-item semi-structured interview, the short version of the Problem Behaviours Assessment for HD (PBA-s). To better characterize the relationship between scores on individual PBA items and overall severity of behavioral symptoms, a nonparametric item response analysis (Ramsay JO, Psychometrika 1991;56:611-630) was performed on the data from year 1 of the study.
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Methods:
The study included 366 subjects (123 affected, 123 premanifest gene carriers, 120 controls). Option Characteristic Curves (OCCs) were generated for all PBA-s items to determine the probability of scoring a particular option in relation to total PBA score. Results: Most items, including Depressed Mood, Anxiety, Irritability, Aggressive Behavior, and Apathy showed generally good discriminative properties, but differences were observed between the three populations (affected, pre-manifest, and control subjects) in terms of their IRT curves. Suicidality was primarily endorsed at the higher levels of overall severity and did not discriminate well at lower PBA scores. A number of symptoms were rarely endorsed in this population at any level of overall behavioral symptom severity, including Delusions, Hallucinations and Disorientation.
Conclusions: These results demonstrate that some items on the PBA-s are more sensitive than others in capturing the overall severity of behavioral symptoms in early and pre-manifest HD, and thus may be more suitable to provide a reliable and valid measure of behavioral symptoms in this population. Objective: To determine whether self-reported measures of disability are predictive of health-related quality of life (QoL) in Huntington's disease (HD). Background: The disability paradox is a term coined to describe patients who report high quality of life despite chronic disability. Patients' objective health status and presence of disability may not correlate with their perception of healthrelated quality of life. This disability paradox has not been examined in patients with HD. Methods: HD patients (n ϭ 25) completed self-reported measures of disability (the Older Americans Resource and Services ADL/IADL Scale, or OARS) and health-related QoL (SF-12 Health Status Survey, Physical and Mental Health Summary Scores). Clinician ratings of disease severity were collected using a five-point Likert scale. Pearson's correlations were used to analyze the relationship between level of disability, healthrelated QoL, and disease severity. Results: Greater disability was associated with lesser physical health QoL (OARS Total r ϭ 0.57, p Ͻ 0.05; OARS ADL r ϭ 0.53, p Ͻ 0.05; OARS IADL r ϭ 0.58, p Ͻ 0.05) and greater disease severity (r ϭ 0.87, p Ͻ 0.001). The OARS ADL subscale was weakly associated with mental health QoL (r ϭ 0.44, p Ͻ 0.05). Total OARS and the OARS IADL subscale did not correlate with mental health QoL (r ϭ 0.41, p ϭ 0.053; r ϭ 0.38, p ϭ 0.075). Greater disease severity correlated with physical health QoL (r ϭ 0.50, p Ͻ 0.05) but not mental health QoL (r ϭ 0.33, p ϭ 0.17).
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Conclusions:
The degree of self-reported disability in HD correlates with self-reported physical health QoL and clinicianrated disease severity but not with self-reported mental health QoL. This example of the disability paradox reinforces the need to evaluate and treat both physical and mental symptoms of HD, as each may contribute independently to quality of life. Objective: To present data from 32 converter participants and 80 matched non-converter participants from the PREDICT-HD study. Methods: All participants were prodromal when they enrolled in the study and all were examined yearly for at least one visit following enrollment. Converters were defined as those individuals who, on at least two consecutive visits, received a score of 4 on the HD Diagnostic Confidence Scale of the UHDRS. Non-converters were individuals who had at least two visits and never received a score of 4. Converters and non-converters were group-matched on age, gender, and CAG repeat length. MRI measurements were obtained for 4 converters 2 years before diagnosis, for 11 converters 1 year before diagnosis, and for 17 converters at the same visit that the diagnosis was made. Results and Discussion: After correcting for intracranial volume (ICV), converters had significantly smaller total brain volume (p ϭ 0.001), total white matter volume (p ϭ 0.004), and total striatum volume (p Ͻ 0.0001), but did not differ on size of cerebellum. A logistic regression model was performed with age and gender included first, with the model selecting the remaining variables one by one. The ratio of striatum/ICV was the only variable selected yielding significant discrimination between converters and non-converters (p Ͻ 0.0001), with correct classification of 78.2% of participants. None of the other MRI measures provided additional significant predictive value to the model. Results indicate that striatal volume, as assessed on MRI, but not other brain measures examined, contributes additional information beyond age and CAG repeat length in predicting onset of diagnosable HD signs. This information, assuming replication in larger samples, highlights the importance of striatal atrophy in the neurobiology of HD, and will be useful for designing clinical trials in which diagnosis of HD is the primary outcome measure. Background: Self-efficacy is defined as individuals' perception of their ability to successfully perform certain tasks or behaviors, or more specifically, as the belief that one can carry out a behavior to achieve a desired goal related to one's health. Higher self-efficacy is correlated with better outcomes in pulmonary disease and fibromyalgia. The role of self-efficacy in disease management has not been examined in Huntington disease (HD). Hypothesis: Individuals with HD have lower self-efficacy for disease self-management than those with Parkinson disease (PD), because of more severe HD clinical course. Methods: Both HD and PD patients were administered the Lorig self-efficacy scale, Mini Mental State Exam (MMSE), Brief Symptom Inventory (BSI-18, psychiatric assessment), and a demographics questionnaire. Global disease severity was clinician-rated using a five-point Likert scale. Results: The sample comprised 22 HD patients and 947 PD patients. The HD patients were younger (54.4 Ϯ 13.0 vs 66.4 Ϯ 11.0, p ϭ 0.01), scored worse on the MMSE (24.74 Ϯ 3.56 vs 28.06 Ϯ 2.93, p Ͻ 0.01), and were less educated (p ϭ 0.016). The two groups did not differ significantly in gender ratio. HD patients reported lower self-efficacy than PD patients in 2 of the 10 Lorig subscales: Ability to Obtain Disease Information ( Background: Previous studies demonstrated that Huntington's disease (HD) impairs the ability to perform to perform online adjustments during reaching movements. It is not clear whether the difficulty is in responding to errors in observed or predicted trajectory. Do patients have trouble observing deviations of the hand from its goal, or does the difficulty lie in predicting where the hand should be based on internal models of the effects of motor commands? Methods: We compared corrections made to two visuomotor perturbations that were equivalent in sensory space, but differed in the nature of the resulting error (goal-related vs effector-related). Subjects made planar reaching movements to guide a screen cursor to a target. Interspersed with baseline trials were perturbation trials, in which either the target jumped to a new location (target jump) or the direction of the cursor was rotated relative to the starting point (rotation). The target jump (to a new direction, Ϯ30 degrees away) and the rotation (Ϯ30 degrees) were spatially matched so as to require the same change in hand movement direction in order to acquire the target. The target jump required a change in movement goal (external error), whereas rotation introduced a mismatch between actual hand position and hand position predicted by subject's visuomotor map (internal model error). Results and Discussion: The corrections made by patients to target jumps were only slightly abnormal, with increased variability and slight undershoot. Their corrections to visuomotor rotation trials, on the other hand, were considerably abnormal. There was a systematic delay in the onset of the correction, and the amplitude of the correction was incomplete. These findings establish a selective impairment in monitoring errors in computation of predicted hand position. A function of the circuits affected by HD may be to monitor internal motor control models that are necessary to guide movements to their targets. Objective: Presented here is a first-in-human study of 3-[ 18 F]fluoro-5-(2-pyridinylethynyl)benzonitrile ( 18 F-FPEB) and PET imaging of mGluR5 in subjects with HD and healthy controls Background: mGluR5 is highly expressed on enkephalinergic striatal neurons and in other neocortical structures. mGluR5 expression may be reduced because of neuron loss or alteration of gene expression. Therefore, mGluR5 may be a useful biomarker for early brain changes in HD, HD progression, or for drug development in HD.
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18 F-FPEB binds mGluR5 with high affinity and specificity. Prior studies in non-human primates demonstrated 18 F-FPEB uptake consistent with the known distribution of mGluR5 expression. Methods: Early HD patients (n ϭ 2) and healthy controls (HC, n ϭ 2) underwent imaging. Subjects received 5 mCi 18 F-FPEB i.v. and serial dynamic PET projection data were acquired for 3 to 6 hours. Regional equilibrium tissue distribution volume measurements were assessed in striatal, neocortical, thalamic, and cerebellar regions. The standardized uptake value (SUV) ratios of targets to a cerebellar reference region were compared in HD and HC. Results: Both HD subjects were female with Htt repeat expansions Ն35. HD_1: age 54 yr, UHDRS subscores motor 13 and TFC 13. HD_2: age 44 yr, UHDRS motor 6 and TFC 11. The HCs were both male, ages 57 and 43 yr. The HCs revealed intense uptake in striatal and cortical gray matter areas, moderate uptake in thalamus, and low, but not absent, uptake in cerebellum. For HCs, mean SUV ratios to cerebellum were, for anterior cingulate, 6.79; for temporal lobe, 6.15; for caudate, 5.44; and for putamen, 4.89. The HD subjects revealed a mean reduction in 18 F-FPEB uptake in striatal regions of 25-30% and temporal lobe and limbic cortical areas of 20 -35%.
Conclusions:
18 F-FPEB is a promising PET radiotracer for evaluating mGluR5 with excellent characteristics for human imaging. This first-in-human study indicates that 18 F-FPEB PET may detect early reductions in striatal and neocortical mGluR5 in relatively mildly symptomatic HD subjects. Future studies are ongoing to evaluate these objectives and other nondopaminergic striatal markers further. Objective: To determine short-and long-term effects on recruitment rates following community-delivered education sessions within a cohort of Huntington disease (HD) support group members in the Pacific Northwest. Background: There has been no systematic measure or comparison of methods utilized in the recruitment of participants to clinical trials. Methods: One year prior to this study, a clinical research education session was given by a community member to HD support groups in the Pacific Northwest. These sessions were purposely low tech and conversational, and questions were encouraged. Participants were made aware of the availability of TRACK-HD during those sessions. One year later, they were made aware of the upcoming local availability of the HART clinical trial. The number of recruits for TRACK-HD and HART was recorded. Results: Just following the education sessions, 6 support group members were recruited to TRACK-HD, which was not offered locally but required the extra effort of several hours of travel and an overnight stay. This represented a 75% rate for recruitment of those meeting study criteria. One year later, without any refresher or follow-up education session, 12 support group members who met criteria for HART were ready to sign up on the first day of official recruitment. This would represent a 75% recruitment rate. Conclusions: One to two hours of community-delivered clinical research education in support groups is a successful recruitment strategy on both the short and the long term. Although numbers in this project were small, the results suggest that a grass-roots, low-tech, and conversational delivery can improve rate of recruitment. Background: Unlike other neurodegenerative disorders, Huntington's disease, with its motor, behavioral, and cognitive deficits and early loss of neurons in the striatum, has a single cause: expanded versions of a polymorphic CAG repeat in the HTT gene (previously HD) of Ն35 units. This uniform starting point permits the development of therapeutics based solely upon the features of the HTT CAG repeat. Methods, Results, and Discussion: We are applying global methods, such as genome-wide gene expression levels, to discover dominant and CAG length-dependent genes and pathways, using cells and tissues bearing the full-range of HTT CAG allele sizes. These phenotypes can potentially point to small molecule or gene modifiers and can be converted into cell-, pathway-or gene-based assays suitable for high-throughput screens to find modifiers of HTT CAG size-dependent effects in models and humans. This genetic approach to therapeutic target discovery has demonstrated that the HTT CAG repeat is a functional polymorphism that, over the non-HD and the HD ranges, affects energy, RNA metabolism, and the cytoskeleton. These HTT CAG size-dependent signatures provide an unbiased read-out for assays with which to find compounds or genes that may slow or halt the earliest phase of the HD disease process. Background: Metabolomics is the systematic study of small molecule metabolites that are the end product of all forces, both endogenous and exogenous, that act upon a specific organism. Interactions among diet, environment, and genes, and their relative contribution to human health and disease, can be elucidated using metabolomics. Although rodent models of HD have been developed, these models do not satisfactorily parallel the brain changes and behavioral features observed in HD patients. Methods: Hallmark features of HD, including nuclear inclusions and neuropil aggregates, were observed in the brains of transgenic monkeys expressing the huntingtin gene. Additionally, the transgenic monkeys showed important clinical features of HD, including dystonia and chorea. Taking advantage of new technology, we developed a method that uses a drop of blood processed with a simple extraction method to remove the proteins and injects directly onto a liquid chromatographyFourier transform mass spectrometry (LC-FTMS) system. In 10 minutes, we are able to reliably detect 2500 metabolites. The method was applied to plasma from 2 HD monkeys (birth to 8 months) and wild-type controls. Results and Discussion: Of the metabolites detected, 19 varied significantly between HD and wild type, 2 of which were important in tryptophan metabolism. These results confirm clinical research showing a disruption in tryptophan metabolism in HD patients. The 32 metabolites that changed most with time were compared with these 19 metabolites, and 2 unknown metabolites were found on both lists. Further investigation into the identity of these metabolites revealed one with a core indole group, suggesting an uncharacterized metabolite of tryptophan. Comparison of transgenic and wild-type monkeys showed putative biomarkers of early disease with relatively few animals. A pilot study is currently underway to test these results in humans and to suggest future therapeutic targets for drug development. 
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LATE-BREAKING RESEARCH
Background:
The UHDRS assesses various aspects of clinical function and capacity in Huntington's disease (HD). Items in the UHDRS motor section are heterogeneous, relate to various aspects of HD motor symptoms, and can be categorized as eye, involuntary, or voluntary movements. Items relating to voluntary movements appear to correlate strongly with the extent of disability, whereas the correlation between chorea and disability is less pronounced. These findings are supported by a preliminary analysis of baseline data from a phase 2 study of pridopidine (ACR16) in patients with HD (ACR16C007). Methods: Motor scales from the UHDRS motor section were analyzed according to their metric properties and correlation with measures of functional disability, assessed by total functional capacity (TFC) and functional assessment (FA) scales. The following motor scales were analyzed, using data from the CARE-HD study dataset: UHDRS motor section items (TMS); TMS excluding eye movements; modified motor scale (mMS: TMS excluding eye movements, chorea, and dystonia), which assessed voluntary movements; chorea; and eye movements. Results: The mMS subscale correlated strongly with TMS ( ϭ 0.89; p Ͻ 0.0001). For functional disability measures, mMS correlated slightly more strongly with FA than the TMS did (-0.53 vs. -0.52, respectively), whereas chorea and eye movements correlated less strongly. The mMS showed improved internal consistency compared with the TMS, and intra-class correlation for the mMS was similar to that for the TMS (ϳ0.90), indicating good test-retest reliability. Intra-class correlations for chorea and eye movements were lower (ϳ0.80).
Conclusions:
The mMS subscale appears to be a valid modification of the UHDRS motor score and has functional relevance, as demonstrated by strong correlations with functional assessments. This subscale of the UHDRS motor sections may offer a simple method of assessing response to treatment in patients with HD. 
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